Successful separation of AAV empty and full capsids using anion exchange chromatography (AEX) requires consideration of both the purification platform and buffer composition to achieve high recovery and purity. Teknova and Sartorius BIA Separations have partnered together to demonstrate the critical nature of these two parameters — highly customized equilibration and elution buffer formulations plus AEX monolith technology — to establish a robust and scalable chromatographic profile. Using a DOE approach, the companies were able to achieve more than 85 percent full AAV capsid enrichment with 80-95 percent recoveries using CIMmultus QA for the polishing step.
Register for this webinar to learn about the critical parameters that affect full capsid enrichment in AAV purification using anion exchange chromatography.
Bella Neufeld, PhD, Director of Research and Development, Teknova
Bella Neufeld is the Director of Research and Development at Teknova, where she manages a gene therapy bioprocessing research program utilizing viral delivery systems for the development of novel products and solutions to help customers accelerate their breakthroughs. Through her leadership, Teknova introduced their first proprietary product line for AAV gene therapy development — AAV-Tek Solutions — based on the findings from her research program and successfully launched the first product in that line: a one-of-a-kind AEX Buffer Screening Kit that optimizes the separation of empty and full capsids during downstream AAV purification. Her work continues to focus on addressing key bottlenecks across the entire gene therapy workflow, with products and solutions in development to support upstream, downstream and analytical pain points.
Previously, as Teknova’s Scientific Director, Bella assembled Teknova’s first internal R&D team when she led the rapid development of a novel transport media for COVID-19 testing. She also oversaw the building of Teknova’s new, state-of-the-art research laboratory. Originally joining the company’s Quality organization in 2018, Bella expanded their scientific capacity by increasing their testing capabilities through instrumentation and new techniques.
After graduating with a Bachelor of Science degree in Chemistry from Sonoma State University, she earned her PhD in chemistry from Colorado State University (CSU) where she set up and maintained two bacterial and tissue culture laboratories for studying drug delivery systems, including solid substrate and nanoparticle platforms. Bella actively presents her latest findings at industry events and her research is regularly featured in industry journals and publications.
Who Should Attend?
- Process development scientists in downstream purification of AAV
- CMO and CDMO leaders interested in establishing a screening platform for AAV full capsid enrichment
What You Will Learn
Attendees will gain insights into:
- Case study for achieving high recovery and purity of AAV particles using Teknova buffers and Sartorius Bia Separations monoliths
- Critical parameters that affect the full capsid enrichment step in AAV purification
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.